The US Food and Drug Administration endorsed Moderna’s respiratory syncytial virus (RSV) vaccine on Friday, giving the company a chance to generate much-needed revenue from a second product.
Moderna’s Vaccine
Moderna’s vaccine has been authorised for the avoidance of RSV-associated respiratory tract infections in adults aged 60 and up.
FDA Approval
Moderna filed for FDA approval in July based on data from a late-stage examination that showed.
Its vaccine was 84% useful for avoiding those symptoms, and its stock fell more than 6% in afternoon trading.
According to Jeffries analyst Michael Yee, the lower efficacy label remains consistent with GSK’s RSV shot Arexvy.
Moderna had previously stated that its vaccine could treat both RSV-associated acute respiratory disease and lower respiratory tract disease.
RSV, which causes symptoms similar to a cold but can be fatal in young children and the elderly, kills approximately 14,000 people over the age of 65 each year.
Spikevax COVID-19 shot
The Cambridge, Massachusetts-based company has been relying on new vaccines.
To compensate for significantly lower demand and sales for its sole advertised product, the Spikevax COVID-19 shot.
Moderna’s RSV vaccine is the first messenger RNA-based (mRNA) vaccine.
That not designed for COVID-19 to be approved in the United States.
mRNA Vaccines
The company claims that mRNA vaccines, which teach the body to produce specific proteins that the immune system.
It can recognise and attack, have the potential to treat a wide range of diseases and are more effective than traditional shots.
“The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform,” Moderna CEO Stephane Bancel said in a statement.
According to LSEG data, analysts expect Moderna’s RSV vaccine to generate $340 million in sales in 2024, increasing to $830.5 million the following year.
To read our blog on “49 diagnosed of Coronavirus in just one day in Pakistan,” click here
